---

 

 

Spray pattern (SP) and plume geometry (PG) produced by spray- and aerosol-generating devices are recognized by regulatory agencies around the world as critical quality attributes (CQAs). They are indicative of the performance of combination drug products and sensitive to minute changes in device design and drug formulation, as well as to patient usage. Understanding the factors that affect these measurements becomes essential to successful drug development and approval. A comprehensive platform for measuring SP and PG, such as the Proveris Scientific SprayVIEW® Measurement System, can be utilized from early development through batch release testing in production. For more information.

Proveris Scientific Corporation
US: +1 508 460-8822
proveris.com

 

---

 

 

The August magazine includes the third in a series of articles from the IPAC-RS Cascade Impaction Working Group concerning the limitations of metrics commonly used in the assessment of aerodynamic particle size distributions (APSDs) of orally inhaled products (OIPs). The current article takes a broader view to discuss why we make quality control measurements such as inhaler APSD. The authors believe that the decision-making framework used to demonstrate product quality consists of both the metrics themselves and the way they are used to make the decision. In the context of inhaler APSD, they contend that good decision-making requires independent assessments of each dimension of the APSD, namely size and mass, which they propose can be achieved via Efficient Data Analysis (EDA).

 

---

 

 

Surface composition and interfacial properties of dry powder particles play a significant role in the processing, structure and functionality of orally inhaled dry powders. Atomic force microscopy (AFM), X-ray photoelectron spectroscopy (XPS) and time-of-flight secondary ion mass spectrometry (ToF-SIMS) have been used to determine the surface chemistry of dry powder formulations, as well as the effects of the particle surface chemical properties on the dissolution and aerosol performance of dry powder inhalers (DPIs). This August magazine article discusses such techniques, which are critical to better understanding powder behavior in the early stages of DPI formulation and may help avoid stability issues later in development.

 

---

 

 

Information on upcoming industry events

Please visit the calendar on Inhalation's website for more conferences, which may change from live to virtual formats and have new dates due to COVID-19.

 

---

 

 

Questions about Inhalation, contact Vicki Schuman, Editor at vschuman@cscpub.com.

w: Inhalation Magazine • e: inhalationmag@cscpub.com

 

 

---

 

This email was sent to you from inhnews@cscpub2.com. To ensure delivery of these emails in your inbox,
please add us to your safe sender list. Privacy Policy • Unsubscribe

CSC Publishing • 1155 Northland Dr • St Paul, MN 55120